Loading
Latest filing published 05 Mar 2026 for 경보제약, €674.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
정희록 (senior executive) discloses dealings in 경보제약 to DART (FSS). We count 5 filings; the first trade dates from 9 January 2025 and the latest from 5 March 2026.
Purchases make up the whole of the open-market record (5 purchases, €674). The totals exclude 4 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 1 purchase and no sales.
The newest entry dates from 5 March 2026: an open-market purchase of €674, in 경보제약. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations